Eriksen, Martina http://orcid.org/0000-0002-4700-2615
Pfeiffer, Per
Rohrberg, Kristoffer Staal
Yde, Christina Westmose
Petersen, Lone Nørgård
Poulsen, Laurids Østergaard
Qvortrup, Camilla
Article History
Received: 1 October 2022
Accepted: 6 December 2022
First Online: 16 December 2022
Declarations
:
: This study was approved by the Ethics Committee of Region Mid-Jutland, Denmark in December 2020. Reference number: 1-10-72-239-20.Written informed content is obtained from each participating patient before inclusion in the study.
: Not applicable.
: All author’s potential competing interests are stated below:ME reports having received a personal fee from Servier.PP reports having a personal financial interest in egetis. Besides this PP reports to have been local PI in trials supported by the following, <u>without</u> financial interests: Amgen, Astra Zeneca, BMS, Boehringer, Celgene, Eisai, Eli Lilly, GSK, Isofol, Merck, MSD, Nordic Drug, Pfizer, Pierre-Fabre, Roche, Sanofi-Aventis, Scandion, Servier, Shire, Taiho.KSR reports having received personal fees from Bayer and Amgen and paid travel and accommodation expenses from Roche and Bristol-Myers Squibb. Besides this KRS reports having received research grants for his institution from the following: Lilly, Roche/Genentech, Bristol-Myers Squibb, Symphogen, Pfizer, Novartis, Loxo, Bayer, Alligator Bioscience, Incyte, Cantargia AB, Genmab, Puma Biotechnology, Orion Clinical, Monta BioScience, and Bioinvent.CWY declare that she has no competing interests.LNP declare that she has no competing interests.LØP reports to have participated in advisory board in MSD.CQ reports having received personal fees from PledPharma, Merck and Roche. CQ reports to have participated in the following advisory boards: Incyte, Bayer, MSD, and Pierre Fabre. CQ reports to have received research grants from Pierre Fabre and Servier.